GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · IEX Real-Time Price · USD
+4.68 (150.00%)
At close: May 20, 2024, 4:00 PM
+0.60 (7.69%)
After-hours: May 20, 2024, 7:59 PM EDT

Company Description

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform.

It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.

The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors.

GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology.

The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017.

GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

GT Biopharma, Inc.
GT Biopharma logo
Country United States
Founded 1965
Industry Biotechnology
Sector Healthcare
Employees 2
CEO Michael Martin Breen

Contact Details

8000 Marina Blvd, Suite 100
Brisbane, California 94005
United States
Phone (800) 304-9888

Stock Details

Ticker Symbol GTBP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000109657
CUSIP Number 36254L209
ISIN Number US36254L3087
Employer ID 94-1620407
SIC Code 2834

Key Executives

Name Position
Michael Martin Breen Interim Chief Executive Officer and Executive Chairman
Manu Ohri Chief Financial Officer and Secretary
Dr. Jeffrey S. Miller M.D. Consulting Chief Scientific Officer, Consulting Chief Medical Officer and Scientific Advisor

Latest SEC Filings

Date Type Title
May 15, 2024 10-Q Quarterly Report
Apr 30, 2024 8-K Current Report
Apr 29, 2024 ARS Filing
Apr 29, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2024 DEF 14A Other definitive proxy statements
Mar 26, 2024 10-K Annual Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 1, 2024 8-K Current Report
Dec 21, 2023 8-K Current Report
Dec 4, 2023 8-K Current Report